MedTrace Logo

The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT

NCT06015815 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2023-08-29

No results posted yet for this study

Summary

The present investigation constitutes a prospective cohort study. The objectives encompass the assessment of miRNA expression levels in total exosomes derived from peripheral circulation tissues of stage III definite KRT NSCLC patients both at the beginning and conclusion of their treatment. Furthermore, an exploration is conducted into the potential correlation existing between alterations in miRNA levels and the incidence of acute treatment-related side effects.

Conditions

  • Non-small Cell Lung Cancer Stage III

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Esra Gümüştepe, M.D · Ankara University

  • Serap Akyürek, M.D · Ankara University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-05
Primary Completion
2020-04-29
Completion
2020-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015815 on ClinicalTrials.gov